Table 2.
Baseline characteristics stratified by having at least one false positive result, recall breast imaging or biopsy not yielding breast cancer, on screening mammography. Know Your Risk: Assessment at Screening (KYRAS) study (N=2019), New York, NY (November 2014–October 2015)
| Characteristic N=2019 |
Had a False Positive Result N=1075 (53.2%) |
Never Had a False Positive Result N=944 (46.8%) |
p-value |
|---|---|---|---|
| Age, years | 0.0442 | ||
| Less than 50 years old | 226 (21.0) | 234 (24.8) | |
| 50 years or older | 849 (79.0) | 710 (75.2) | |
| Race/ethnicity | 0.3431 | ||
| Hispanic | 837 (77.9) | 705 (74.7) | |
| Non-Hispanic white | 105 (9.8) | 99 (10.5) | |
| Non-Hispanic black | 93 (8.7) | 101 (10.7) | |
| Other | 40 (3.7) | 39 (4.1) | |
| Body mass index, kg/m2 | 0.0455 | ||
| Underweight (<18.5) | 18 (1.7) | 13 (1.4) | |
| Normal weight (18.5–24.9) | 308 (28.7) | 254 (26.9) | |
| Overweight (25–29.9) | 405 (37.7) | 319 (33.8) | |
| Obese (≥30) | 344 (32.0) | 358 (37.9) | |
| Frequency of screening* | <0.0001 | ||
| Annual | 836 (77.8) | 563 (59.6) | |
| Biennial | 139 (12.9) | 196 (20.8) | |
| Every 3+ years | 69 (6.4) | 137 (14.5) | |
| First mammogram | 31 (2.9) | 48 (5.1) | |
| Breast density** | 0.0002 | ||
| Low breast density | 712 (66.2) | 698 (73.9) | |
| High breast density | 363 (33.8) | 246 (26.1) | |
| Breast cancer risk status*** | 0.0583 | ||
| Low or average risk | 791 (73.6) | 729 (77.2) | |
| High risk | 284 (26.4) | 215 (22.8) |
Yearly screening frequency was determined as a median of 9 to 18 months between screening mammograms. Biennial screening frequency was determined as a median of >18 to 30 months between screening mammograms. Every 3+ years was determined as greater than a median of 30 months between screening mammograms.
Breast density was dichotomized as low [almost entirely fatty (<25% density) or scattered areas of fibroglandular density (25–50%)] or high [heterogeneously dense (51–75%) or “extremely dense” (>75%)]
High breast cancer risk status for breast cancer was determined as having greater than 1.66% 5-year risk or 20% lifetime risk based upon the Gail model or a score of 6 or greater on the modified Six-Point Scale, which indicates eligibility for BRCA genetic testing.